These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 11123433)

  • 1. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
    Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
    Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum (II) suspended in lipiodol.
    Kishimoto S; Miyazawa K; Fukushima S; Takeuchi Y
    Jpn J Cancer Res; 2000 Jan; 91(1):99-104. PubMed ID: 10744050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro cytotoxicity of cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol in rat hepatoma AH-109A cells and human tumor cell lines.
    Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
    Biol Pharm Bull; 2000 Apr; 23(4):487-91. PubMed ID: 10784433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between intracellular accumulation and cytotoxic activity of cis-[((1R, 2R)-1, 2-cyclohexanediamine-N, N')bis(myristato)]platinum(II) suspended in Lipiodol.
    Kishimoto S; Ohtani A; Fukuda H; Fukushima S; Takeuchi Y
    Biol Pharm Bull; 2003 May; 26(5):683-6. PubMed ID: 12736512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro release of SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol.
    Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
    Biol Pharm Bull; 2000 May; 23(5):637-40. PubMed ID: 10823679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration.
    Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
    Biol Pharm Bull; 2000 Mar; 23(3):344-8. PubMed ID: 10726891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells.
    Kishimoto S; Yasuda M; Suzuki R; Fukushima S
    Biometals; 2016 Dec; 29(6):1075-1083. PubMed ID: 27787693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
    Kido Y; Khokhar AR; al-Baker S; Siddik ZH
    Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
    Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ; Kelland LR; Harrap KR
    Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Na+, K+-ATPase alpha1 subunit in the intracellular accumulation of cisplatin.
    Kishimoto S; Kawazoe Y; Ikeno M; Saitoh M; Nakano Y; Nishi Y; Fukushima S; Takeuchi Y
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):84-90. PubMed ID: 16044341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
    Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis.
    Hanada M; Baba A; Tsutsumishita Y; Noguchi T; Yamaoka T; Chiba N; Nishikaku F
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):473-83. PubMed ID: 19104812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
    Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
    Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
    Esaki T; Nakano S; Masumoto N; Fujishima H; Niho Y
    Int J Cancer; 1996 Feb; 65(4):479-84. PubMed ID: 8621231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line.
    Asada N; Tsuchiya H; Ueda Y; Tomita K
    Anticancer Res; 1998; 18(3A):1765-8. PubMed ID: 9673402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
    Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
    Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.